Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
frontMIND: tafasitamab + lenalidomide + R-CHOP versus placebo + R-CHOP in previously untreated high-risk DLBCL
2022-500237-92-00Phase 3Authorised
- Sponsor
- Incyte
- Start
- Apr 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial in diffuse large B-cell lymphoma (DLBCL) comparing Tafasitamab + lenalidomide + R-CHOP with Placebo + R-CHOP (2 arms). Primary endpoint: Progression-free survival. Planned start Apr 2021; status: authorised.
02
Drugs
tafasitamablenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2022-500237-92-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500237-92-00.